Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on February 27, 2012, by Jazz Pharmaceuticals Public Limited Company. The filing primarily addresses the results of operations and financial condition following a merger transaction completed on January 18, 2012, between Jazz Pharmaceuticals, Inc. ("JPI") and Azur Pharma Public Limited Company ("Azur Pharma"). JPI is treated as the acquiring company for accounting purposes, and the transaction is accounted for as a reverse acquisition.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references a press release (Exhibit 99.1) issued on February 27, 2012, which contains the financial results for JPI for the full year and fourth quarter ended December 31, 2011, as well as selected 2011 financial results for the historic Azur Pharma business.
Material Changes
The primary material change reported is the structural combination of JPI and Azur Pharma into Jazz Pharmaceuticals Public Limited Company. Consequently, the consolidated financial statements of JPI through January 18, 2012, now serve as the Company's consolidated financial statements for those periods.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a detailed discussion of risks within the text of the 8-K itself. It explicitly states that the information in Item 2.02 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings.
Key Facts for Investor Verification
- Verify the specific financial figures for JPI and Azur Pharma by reviewing the press release attached as Exhibit 99.1, as this 8-K does not list the numbers directly.
- Confirm the accounting treatment of the merger as a reverse acquisition where JPI is the accounting acquirer.
- Note that the financial data referenced in this filing is not incorporated by reference into future SEC filings by the Company.
- Review the press release for any specific details regarding the historic Azur Pharma business results for 2011.